A detailed history of Deep Track Capital, LP transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Deep Track Capital, LP holds 3,282,000 shares of DYN stock, worth $78.7 Million. This represents 4.35% of its overall portfolio holdings.

Number of Shares
3,282,000
Previous 4,000,000 17.95%
Holding current value
$78.7 Million
Previous $141 Million 16.49%
% of portfolio
4.35%
Previous 4.63%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$31.94 - $47.04 $22.9 Million - $33.8 Million
-718,000 Reduced 17.95%
3,282,000 $118 Million
Q2 2024

Aug 14, 2024

SELL
$23.65 - $35.63 $13.1 Million - $19.8 Million
-555,383 Reduced 12.19%
4,000,000 $141 Million
Q1 2024

May 15, 2024

BUY
$13.06 - $29.18 $33.4 Million - $74.6 Million
2,555,383 Added 127.77%
4,555,383 $129 Million
Q4 2023

Feb 14, 2024

SELL
$6.62 - $13.64 $2.67 Million - $5.51 Million
-403,672 Reduced 16.79%
2,000,000 $26.6 Million
Q3 2023

Nov 14, 2023

SELL
$8.6 - $12.18 $827,664 - $1.17 Million
-96,240 Reduced 3.85%
2,403,672 $21.5 Million
Q2 2023

Aug 14, 2023

BUY
$8.53 - $14.28 $1.41 Million - $2.36 Million
165,279 Added 7.08%
2,499,912 $28.1 Million
Q1 2023

May 15, 2023

SELL
$10.88 - $15.0 $3.8 Million - $5.24 Million
-349,567 Reduced 13.02%
2,334,633 $26.9 Million
Q4 2022

Feb 14, 2023

SELL
$9.37 - $13.8 $4.69 Million - $6.9 Million
-500,000 Reduced 15.7%
2,684,200 $31.1 Million
Q3 2022

Nov 14, 2022

SELL
$7.2 - $15.17 $2.27 Million - $4.79 Million
-315,800 Reduced 9.02%
3,184,200 $40.4 Million
Q1 2022

May 16, 2022

BUY
$6.52 - $12.27 $7.87 Million - $14.8 Million
1,207,750 Added 52.69%
3,500,000 $33.7 Million
Q4 2021

Feb 14, 2022

BUY
$11.89 - $16.07 $27.3 Million - $36.8 Million
2,292,250 New
2,292,250 $27.3 Million

Others Institutions Holding DYN

About Dyne Therapeutics, Inc.


  • Ticker DYN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,765,400
  • Market Cap $1.24B
  • Description
  • Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...
More about DYN
Track This Portfolio

Track Deep Track Capital, LP Portfolio

Follow Deep Track Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deep Track Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Deep Track Capital, LP with notifications on news.